Skip to main content
SpringerLink
Log in

Progestogens in Endometrial Cancer

  • Chapter
Progestogens in Obstetrics and Gynecology

  • 1155 Accesses

Abstract

Hysterectomy is the treatment choice for patients with endometrial cancer, but progesterone may be an acceptable option for young women who wish to preserve their fertility or for women with severe co-morbidities.

Although progestin therapy of low-grade early-stage endometrial carcinoma has been utilized for years, many questions remain unanswered.

Cohort studies show a high chance of disease regression (65–76 %) and encouraging live birth rates (28–35 %). The risk of disease relapse during follow-up is significant but overall outcome and survival are not jeopardized by well controlled temporary conservative treatment.

Young women desiring to pursue this treatment need to undergo thorough counseling, extensive work-up, and close follow-up and should undergo hysterectomy once family planning is complete.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jemal A, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Duska LR, et al. Endometrial cancer in women 40 years old or younger. Gynecol Oncol. 2001;83(2):388–93.

    Article  CAS  PubMed  Google Scholar 

  3. Gitsch G, et al. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol. 1995;85(4):504–8.

    Article  CAS  PubMed  Google Scholar 

  4. Lajer H, et al. Survival after stage IA endometrial cancer; can follow-up be altered? A prospective nationwide Danish survey. Acta Obstet Gynecol Scand. 2012;91(8):976–82.

    Article  PubMed  Google Scholar 

  5. Mourits MJ, et al. Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol. 2010;11(8):763–71.

    Article  PubMed  Google Scholar 

  6. Obermair A, et al. Total laparoscopic hysterectomy versus total abdominal hysterectomy for obese women with endometrial cancer. Int J Gynecol Cancer. 2005;15(2):319–24.

    Article  CAS  PubMed  Google Scholar 

  7. Cade TJ, et al. Progestogen treatment options for early endometrial cancer. BJOG. 2010;117(7):879–84.

    Article  CAS  PubMed  Google Scholar 

  8. Baker J, et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263–70.

    Article  CAS  PubMed  Google Scholar 

  9. Matthews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief. 2009;21:1–8.

    PubMed  Google Scholar 

  10. Lee NK, et al. Prognostic factors for uterine cancer in reproductive-aged women. Obstet Gynecol. 2007;109(3):655–62.

    Article  PubMed  Google Scholar 

  11. Walsh C, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol. 2005;106(4):693–9.

    Article  PubMed  Google Scholar 

  12. Koskas M, et al. Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril. 2012;98(5):1229–35.

    Article  PubMed  Google Scholar 

  13. Leitao Jr MM, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol. 2009;113(1):105–8.

    Article  PubMed  Google Scholar 

  14. Daniel AG, Peters 3rd WA. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol. 1988;71(4):612–4.

    CAS  PubMed  Google Scholar 

  15. Sironi S, et al. Myometrial invasion by endometrial carcinoma: assessment by MR imaging. AJR Am J Roentgenol. 1992;158(3):565–9.

    Article  CAS  PubMed  Google Scholar 

  16. Wu LM, et al. Predictive value of T2-weighted imaging and contrast-enhanced MR imaging in assessing myometrial invasion in endometrial cancer: a pooled analysis of prospective studies. Eur Radiol. 2013;23(2):435–49.

    Article  PubMed  Google Scholar 

  17. Manfredi R, et al. Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology. 2004;231(2):372–8.

    Article  PubMed  Google Scholar 

  18. Gotlieb WH. Fertility preserving treatments for endometrial cancer: the unanswered questions. Gynecol Oncol. 2013;129(1):1–2.

    Article  PubMed  Google Scholar 

  19. Kim CH, et al. Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol. 2013;131(3):714–9.

    Article  PubMed  Google Scholar 

  20. Lancaster JM, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107(2):159–62.

    Article  PubMed  Google Scholar 

  21. Kauff ND. How should women with early-onset endometrial cancer be evaluated for lynch syndrome? J Clin Oncol. 2007;25(33):5143–6.

    Article  PubMed  Google Scholar 

  22. Park JY, et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013;49(4):868–74.

    Article  CAS  PubMed  Google Scholar 

  23. Penner KR, et al. Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy. Gynecol Oncol. 2012;124(3):542–8.

    Article  PubMed  Google Scholar 

  24. Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer. 2005;41(5):673–5.

    Article  CAS  PubMed  Google Scholar 

  25. Janzen DM, et al. Progesterone receptor signaling in the microenvironment of endometrial cancer influences its response to hormonal therapy. Cancer Res. 2013;73(15):4697–710.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Thigpen JT, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999;17(6):1736–44.

    CAS  PubMed  Google Scholar 

  27. Ramirez PT, et al. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol. 2004;95(1):133–8.

    Article  CAS  PubMed  Google Scholar 

  28. Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol. 2004;95(3):762–4.

    Article  CAS  PubMed  Google Scholar 

  29. Laurelli G, et al. Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol. 2011;120(1):43–6.

    Article  PubMed  Google Scholar 

  30. Kim MK, et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol. 2013;209(4):358e1–4.

    Article  Google Scholar 

  31. Minig L, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol. 2011;22(3):643–9.

    Article  CAS  PubMed  Google Scholar 

  32. Gunderson CC, et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–82.

    Article  CAS  PubMed  Google Scholar 

  33. Ashino-Fuse H, et al. Medroxyprogesterone acetate, an anti-cancer and anti-angiogenic steroid, inhibits the plasminogen activator in bovine endothelial cells. Int J Cancer. 1989;44(5):859–64.

    Article  CAS  PubMed  Google Scholar 

  34. Ushijima K, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol. 2007;25(19):2798–803.

    Article  CAS  PubMed  Google Scholar 

  35. Kelley RM, Baker WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med. 1961;264:216–22.

    Article  CAS  PubMed  Google Scholar 

  36. Gallos ID, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol. 2012;207(4):266e1–12.

    Article  Google Scholar 

  37. Park JY, et al. Progestin re-treatment in patients with recurrent endometrial adenocarcinoma after successful fertility-sparing management using progestin. Gynecol Oncol. 2013;129(1):7–11.

    Article  CAS  PubMed  Google Scholar 

  38. Kim ML, Seong SJ. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. Obstet Gynecol Sci. 2013;56(2):67–75.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Banno K, et al. Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review). Int J Oncol. 2012;40(6):1755–62.

    CAS  PubMed  Google Scholar 

  40. Varma R, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia–a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139(2):169–75.

    Article  CAS  PubMed  Google Scholar 

  41. Montz FJ, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186(4):651–7.

    Article  CAS  PubMed  Google Scholar 

  42. Kim MK, et al. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer. Gynecol Oncol. 2013;130(3):470–3.

    Article  CAS  PubMed  Google Scholar 

  43. Wright JD, et al. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol. 2009;27(8):1214–9.

    Article  PubMed  Google Scholar 

  44. Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta Obstet Gynecol Scand. 1984;63(5):441–50.

    Article  CAS  PubMed  Google Scholar 

  45. Piver MS, et al. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer. 1980;45(2):268–72.

    Article  CAS  PubMed  Google Scholar 

  46. Podratz KC, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol. 1985;66(1):106–10.

    CAS  PubMed  Google Scholar 

  47. Whitney CW, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):4–9.

    Article  CAS  PubMed  Google Scholar 

  48. Fiorica JV, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):10–4.

    Article  CAS  PubMed  Google Scholar 

  49. Pandya KJ, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol. 2001;24(1):43–6.

    Article  CAS  PubMed  Google Scholar 

  50. Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol. 2006;58(3):242–56.

    Article  PubMed  Google Scholar 

  51. Katsuki Y, et al. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins. Cancer. 1997;79(1):169–76.

    Article  CAS  PubMed  Google Scholar 

  52. Nakamura M, et al. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur J Pharmacol. 1999;386(1):33–40.

    Article  CAS  PubMed  Google Scholar 

  53. Katayama H, et al. Effect of dienogest administration on angiogenesis and hemodynamics in a rat endometrial autograft model. Hum Reprod. 2010;25(11):2851–8.

    Article  CAS  PubMed  Google Scholar 

  54. Shimizu Y, et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol Hum Reprod. 2009;15(10):693–701.

    Article  CAS  PubMed  Google Scholar 

  55. Shimizu Y, et al. Dienogest, a synthetic progestin, inhibits prostaglandin E2 production and aromatase expression by human endometrial epithelial cells in a spheroid culture system. Steroids. 2011;76(1–2):60–7.

    Article  CAS  PubMed  Google Scholar 

  56. Yang S, et al. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med. 2011;12(64):205–12.

    PubMed  Google Scholar 

  57. Ren Y, et al. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet Cytogenet. 2007;175(2):107–16.

    Article  CAS  PubMed  Google Scholar 

  58. Xiong Y, et al. Histone deacetylase inhibitors decrease DNA methyltransferase-3B messenger RNA stability and down-regulate de novo DNA methyltransferase activity in human endometrial cells. Cancer Res. 2005;65(7):2684–9.

    Article  CAS  PubMed  Google Scholar 

  59. Balch C, et al. Role of epigenomics in ovarian and endometrial cancers. Epigenomics. 2010;2(3):419–47.

    Article  CAS  PubMed  Google Scholar 

  60. Ai Z, et al. Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway. Cancer. 2010;116(15):3603–13.

    Article  CAS  PubMed  Google Scholar 

  61. Bokhman JV, et al. Can primary endometrial carcinoma stage I be cured without surgery and radiation therapy? Gynecol Oncol. 1985;20(2):139–55.

    Article  CAS  PubMed  Google Scholar 

  62. Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90(3):434–40.

    Article  CAS  PubMed  Google Scholar 

  63. Kim YB, et al. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer. 1997;79(2):320–7.

    Article  CAS  PubMed  Google Scholar 

  64. Imai M, et al. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol. 2001;22(3):217–20.

    CAS  PubMed  Google Scholar 

  65. Kaku T, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett. 2001;167(1):39–48.

    Article  CAS  PubMed  Google Scholar 

  66. Wang CB, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer. 2002;94(8):2192–8.

    Article  PubMed  Google Scholar 

  67. Gotlieb WH, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol. 2003;102(4):718–25.

    Article  CAS  PubMed  Google Scholar 

  68. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril. 2003;80(6):1315–24.

    Article  PubMed  Google Scholar 

  69. Niwa K, et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG. 2005;112(3):317–20.

    Article  CAS  PubMed  Google Scholar 

  70. Ota T, et al. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer. 2005;15(4):657–62.

    Article  CAS  PubMed  Google Scholar 

  71. Yahata T, et al. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum Reprod. 2006;21(4):1070–5.

    Article  CAS  PubMed  Google Scholar 

  72. Yang YC, et al. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer. Gynecol Oncol. 2005;99(2):287–93.

    Article  CAS  PubMed  Google Scholar 

  73. Le Digabel JF, et al. Young women with atypical endometrial hyperplasia or endometrial adenocarcinoma stage I: will conservative treatment allow pregnancy? Results of a French multicentric survey. Gynecol Obstet Fertil. 2006;34(1):27–33.

    Article  PubMed  Google Scholar 

  74. Elizur SE, et al. Outcome of in vitro fertilization treatment in infertile women conservatively treated for endometrial adenocarcinoma. Fertil Steril. 2007;88(6):1562–7.

    Article  PubMed  Google Scholar 

  75. Minaguchi T, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. Cancer Lett. 2007;248(1):112–22.

    Article  CAS  PubMed  Google Scholar 

  76. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol. 2007;31(7):988–98.

    Article  PubMed  Google Scholar 

  77. Yamazawa K, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. Hum Reprod. 2007;22(7):1953–8.

    Article  CAS  PubMed  Google Scholar 

  78. Li HZ, Chen XN, Qiao J. Letrozole as primary therapy for endometrial hyperplasia in young women. Int J Gynaecol Obstet. 2008;100(1):10–2.

    Article  CAS  PubMed  Google Scholar 

  79. Eftekhar Z, et al. Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients. Int J Gynecol Cancer. 2009;19(2):249–52.

    Article  PubMed  Google Scholar 

  80. Hahn HS, et al. Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer. 2009;19(6):1068–73.

    Article  PubMed  Google Scholar 

  81. Han AR, et al. Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia. Int J Gynecol Cancer. 2009;19(1):147–51.

    Article  PubMed  Google Scholar 

  82. Signorelli M, et al. Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG. 2009;116(1):114–8.

    Article  CAS  PubMed  Google Scholar 

  83. Yu M, et al. Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women. Zhonghua Fu Chan Ke Za Zhi. 2006;41(4):242–5.

    PubMed  Google Scholar 

  84. Mao Y, et al. Outcomes of conservative therapy for young women with early endometrial adenocarcinoma. Fertil Steril. 2010;93(1):283–5.

    Article  PubMed  Google Scholar 

  85. Mazzon I, et al. Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril. 2010;93(4):1286–9.

    Article  PubMed  Google Scholar 

  86. Park H, et al. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium. Arch Gynecol Obstet. 2012;285(2):473–8.

    Article  CAS  PubMed  Google Scholar 

  87. Perri T, et al. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. Int J Gynecol Cancer. 2011;21(1):72–8.

    Article  PubMed  Google Scholar 

  88. Thigpen T, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19(2):364–7.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Jewish General Hospital & Lady Davis Research Institute, McGill University, Montreal, QC, Canada

    Ido Laskov M.D.

  2. Division of Gynecologic Oncology, Jewish General Hospital, McGill University, 3755 Cote Ste Catherine Road, Room E716, Montreal, QC, Canada, H3T1E2

    Walter H. Gotlieb M.D., Ph.D.

Authors
  1. Ido Laskov M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Walter H. Gotlieb M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walter H. Gotlieb M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Tel Aviv University, Tel Aviv, Tel Aviv, Israel

    Howard J.A. Carp

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Laskov, I., Gotlieb, W.H. (2015). Progestogens in Endometrial Cancer. In: Carp, H. (eds) Progestogens in Obstetrics and Gynecology. Springer, Cham. https://doi.org/10.1007/978-3-319-14385-9_11

Download citation

Publish with us

Policies and ethics

Search

Navigation